Why the study?
Does the AKR1C3 IVS4-212 GG genotype affect doxorubicin pharmacodynamics and survival in Asian breast cancer patients?
Does the AKR1C3 IVS4-212 GG genotype affect doxorubicin pharmacodynamics and survival in Asian breast cancer patients?
The AKR1C3 IVS4-212 GG genotype is associated with greater hematological toxicity but improved progression-free and overall survival in Asian breast cancer patients receiving doxorubicin.
No takes yet. Share an insight, caveat, or question.
Should not yet guide doxorubicin dosing by AKR1C3 genotype in breast cancer; leaves open prospective validation in Asian cohorts.
Voon et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: